Shares of Xoma (XOMA) are down $7.36 to $27.00 in premarket trading after the company’s partner Rezolute (RZLT) announced that ersodetug failed in a Phase 3 congenital hyperinsulinism study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XOMA: